Trial Profile
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin and Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age greater than or equal to 60 Years)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Cytarabine; Daunorubicin; Fludarabine
- Indications Acute myeloid leukaemia; Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms ECOG-ACRIN E2906
- 12 Dec 2023 Results of prospective patient-reported outcomes (PRO) assessment of HRQoL and fatigue to understand treatment impact from the patients(pts) perspective, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results of post remission data from the prospective ECOG-ACRIN E2906 study assessing all patients who received alloSCT either on protocol during first remission (CR1) or at other post induction time-points, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 23 Feb 2021 Planned primary completion date changed from 15 Jan 2021 to 15 Mar 2021.